Carlsbad, CA, May 27, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing ...
Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging ...
PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and ...
Patients with Crohn's disease who undergo terminal ileum resection have a significantly higher risk of developing colorectal cancer (CRC) and colorectal polyps than those who do not undergo resection.
Terminal ileum intubation is considered the completion step of colonoscopy and is usually performed to assess the ileum. The histological examination of the ileal mucosa, which is acquired during ...
Investors registered to attend the conference who wish to meet with Palisade Bio management should contact the Leerink one-on-one desk to request a meeting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results